Articles By: admin

Thoughts on combination therapies

0 May 31, 2014 9:27 am

orning it’s Day 1 of ASCO 2014 and it’s already a mad house. The combo Phase 1 study of ipilimumab, dabrafenib (BRAF inhib) and trametinib (MEK inhib) has been presented. Interestingly, the doublet combination (Ipi plus Dab) did not […]

ASCO 2014 Saturday Melanoma Preview

0 May 30, 2014 10:22 pm

pmental Therapeutics AM session: Oral abstract: Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation–positive unresectable or metastatic melanoma (MM). [This is interesting because […]

ASCO preview 2014: TheMelanomaCenter edition

0 May 30, 2014 8:20 pm

17;s once again time for ASCO, or the American Society of Clinical Oncology, where more than 25,000 oncology doctors as well as countless pharma, biotech, genomic testing, and assorted media types converge on downtown Chicago and the McCormick Convention Center […]

Review of BRAF/MEK Combo NEJM data

0 October 3, 2012 4:32 pm

eat results from multiple clinical trials treating advanced melanoma keep coming, as the NEJM publication from this GSK (Glaxo SmithKline)-sponsored trial recently affirmed. This trial was a Phase I-II trial of combination therapy for advanced melanoma harboring a v600 […]

Sequence and Timing of Melanoma Therapy

0 June 3, 2012 10:41 pm

oes a (relative) wealth of melanoma treatment “riches” create? Several words come to mind. Confusion. Creativity. Imagination. Dialogue. Conflict. Bias. Conviction (of ideas). Such is the state of the disease over the past year, since the approval of ipilimumab […]

ASCO 2012 Melanoma Posters

0 June 3, 2012 9:52 pm

ost will cover both the “discussed” posters, generally felt to be more important by ASCO organizers, and the “general” posters. Instead of going through all the posters, I have selected the ones I found most interesting: A phase II single […]

Anti-PD-1 Therapy

0 June 2, 2012 5:14 am

CO press releases have begun; first up to the plate is BMS and their anti-PD-1 antibody. Similar to ipilimumab, this drug works through immune system checkpoint modulation.In other words, it works by releasing the natural inhibition of our immune […]

ASCO 2012 schedule

0 June 2, 2012 4:35 am

s the schedule of melanoma-related events for ASCO this year. It is possible that I have missed some Phase I presentations with melanoma patients included. Friday June 1: No sessions Saturday, June 2: 8 am “New Options, New Questions: […]

ASCO 2012 preview

ASCO 2012 preview

0 June 1, 2012 8:07 pm

ear’s ASCO (American Society of Clinical Oncology) meeting will once again be held in Chicago IL at the mammoth McCormick Place Convention Center. The overall theme for this year’s meeting is, “Collaborating to Conquer Cancer.” This is an interesting […]

Today’s Thought: What matters in treatment choices?

24 December 10, 2011 12:32 am

y melanoma meetings, the issue of treatment of metastatic disease with Interleukin-2 comes up. The room quickly divides into two sides, the true-believers and not-in-my-cancer-centers. The two groups both mean well and are both completely versed in the pros […]

Shopping Cart (0 Items)
Your cart is empty!


Subtotal: $0.00
Total: $0.00